Ipsen: Prostatic Neoplasms trials

The registry lists 26 Prostatic Neoplasms studies with Ipsen as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 2Phase 2 6Phase 3 7Phase 4 2No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the ProstateCompletedNCT05590793Phase 3Results posted
• Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the ProstateCompletedNCT05458856Phase 3Results posted
• A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerTerminatedNCT04179864Phase 1/2Results posted
• Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02057666Phase 3Results posted
• A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.CompletedNCT01753297Phase 4Results posted
• A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based ChemotherapyTerminatedNCT01732549Phase 2Results posted
• Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate CancerCompletedNCT01715129Phase 3Results posted
• GP Extended Action TriptorelinTerminatedNCT01673984Phase 4Results posted
• Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate CancerTerminatedNCT01374087Phase 2Results posted
• Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer PatientsTerminatedNCT01313273Phase 3Results posted
• Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mgCompletedNCT01257425Phase 2Results posted
• Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate CancerCompletedNCT01020448Phase 3Results posted
• A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in ItalyCompletedNCT05759273
• Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.CompletedNCT04593420
• Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist TherapyCompletedNCT03516110
• To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer PatientsCompletedNCT03017313
• Quality of Life of Patients With Locally Advanced and Metastatic Prostate CancerCompletedNCT02853409
• Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.CompletedNCT02630641
• Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) AnaloguesCompletedNCT02542501
• Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate CancerCompletedNCT02238366
• Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.TerminatedNCT01562522Phase 2
• Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant StateCompletedNCT01560858
• A Long-term Observational Study Cohort in Patients With Advanced Prostate CancerCompletedNCT01383863
• BN83495 in Prostate CancerCompletedNCT00790374Phase 1
• Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)TerminatedNCT00444639Phase 2
• Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate CancerTerminatedNCT00415246Phase 3